ArticleCureus2025
Incidence of Pyogenic Arthritis in Aragón, Spain, From 2015 to 2023.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim The main objective of our study is to analyze the evolution of hospitalizations coded M00.9 (pyogenic arthritis) in Aragón (Spain) since 2015. Methods This is an observational, descriptive, and analytical study analyzing cases coded as pyogenic arthritis (M00.9), according to the International Classification of Diseases, version 10 (ICD-10), in both public and private hospitals in the Autonomous Community of Aragón between 2015 and 2023. Primary data were obtained from Aragón's Health Big Data (BIGAN), linked to the Aragón Health Sciences Institute, and the data were analyzed by us, considering a p-value <0.05 as statistically significant. Results A total of 261 patients with pyogenic arthritis were identified. The incidence of pyogenic arthritis showed an increasing trend, with an incidence of 1.76/100,000 inhabitants in 2016 and 1.36/100,000 inhabitants in 2021, which rose to 5.65/100,000 inhabitants in 2022, followed by a decrease in 2023 without reaching the previous levels of 2021. Men accounted for 160 (61.3%) of the 261 patients with pyogenic arthritis, while 101 were women (38.7%). The mean age was 54.96±29.21 years, with no significant age differences between men and women (men 54.8±27.3; women 55.22±32.14). Among zero- to four-year-old children, there were 35 cases (13.41%) (18 boys and 17 girls). There were 119 cases (45.59%) in patients aged >65 years (66 men, 55.46%). In 2016, the incidence was 3.41 cases/100,000 persons aged zero to four years, and 2.87 cases/100,000 persons aged >65 years; in 2022, it was 8.04 cases/100,000 persons aged zero to four years and 12.97 cases/100,000 persons aged >65 years. The monthly distribution did not show significant differences; the highest incidence was recorded in August (28 patients) and September (31 patients). A total of 90.2% of pyogenic arthritis cases were treated in the public health system. The mean length of hospital stay was 13.03±14.53 days. Readmission occurred in 23.37% of patients with pyogenic arthritis. The most frequent comorbidities were: chronic hematologic disease (37.4%), hypertension (35.11%), dyslipidemia (29.01%), rheumatologic disorder (24.05%), mental disorder (20.23%), diabetes (19.85%), and vascular disease (19.47%). Conclusions In 2022, there was a significant increase in pyogenic arthritis compared to previous years, with a decrease in 2023 that did not return to the levels prior to 2021. There was a predominance of pyogenic arthritis in men.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.